Novel somatic mutations to PI3K pathway genes in metastatic melanoma

Austin Y. Shull, Alicia Latham-Schwark, Poornema Ramasamy, Kristin Leskoske, Dora Oroian, Marc R. Birtwistle, Phillip J. Buckhaults

Research output: Contribution to journalArticlepeer-review

75 Scopus citations

Abstract

Background: BRAFV600 inhibitors have offered a new gateway for better treatment of metastatic melanoma. However, the overall efficacy of BRAFV600 inhibitors has been lower than expected in clinical trials, and many patients have shown resistance to the drug's effect. We hypothesized that somatic mutations in the Phosphoinositide 3-Kinase (PI3K) pathway, which promotes proliferation and survival, may coincide with BRAFV600 mutations and contribute to chemotherapeutic resistance. Methods: We performed a somatic mutation profiling study using the 454 FLX pyrosequencing platform in order to identify candidate cancer genes within the MAPK and PI3K pathways of melanoma patients. Somatic mutations of theses candidate cancer genes were then confirmed using Sanger sequencing. Results: As expected, BRAFV600 mutations were seen in 51% of the melanomas, whereas NRAS mutations were seen in 19% of the melanomas. However, PI3K pathway mutations, though more heterogeneous, were present in 41% of the melanoma, with PTEN being the highest mutated PI3K gene in melanomas (22%). Interestingly, several novel PI3K pathway mutations were discovered in MTOR, IRS4, PIK3R1, PIK3R4, PIK3R5, and NFKB1. PI3K pathway mutations co-occurred with BRAFV600 mutations in 17% of the tumors and co-occurred with 9% of NRAS mutant tumors, implying cooperativity between these pathways in terms of melanoma progression. Conclusions: These novel PI3K pathway somatic mutations could provide alternative survival and proliferative pathways for metastatic melanoma cells. They therefore may be potential chemotherapeutic targets for melanoma patients who exhibit resistance to BRAFV600 inhibitors.

Original languageEnglish
Article numbere43369
JournalPLoS ONE
Volume7
Issue number8
DOIs
StatePublished - 17 Aug 2012
Externally publishedYes

Fingerprint

Dive into the research topics of 'Novel somatic mutations to PI3K pathway genes in metastatic melanoma'. Together they form a unique fingerprint.

Cite this